Cargando…

Atherogenic subfractions of lipoproteins in the treatment of metabolic syndrome by physical activity and diet – the RESOLVE trial

BACKGROUND: We aimed to comprehensively evaluate lipoprotein profile including lipid particle size following a lifestyle intervention in metabolic syndrome (MetS) volunteers and to assess the associations between lipoprotein subfractions and carotid-intima-media-thickness (CIMT) – a surrogate indica...

Descripción completa

Detalles Bibliográficos
Autores principales: Dutheil, Frédéric, Walther, Guillaume, Chapier, Robert, Mnatzaganian, George, Lesourd, Bruno, Naughton, Geraldine, Verney, Julien, Fogli, Anne, Sapin, Vincent, Duclos, Martine, Vinet, Agnès, Obert, Philippe, Courteix, Daniel, Lac, Gérard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4115215/
https://www.ncbi.nlm.nih.gov/pubmed/25015177
http://dx.doi.org/10.1186/1476-511X-13-112
_version_ 1782328523010080768
author Dutheil, Frédéric
Walther, Guillaume
Chapier, Robert
Mnatzaganian, George
Lesourd, Bruno
Naughton, Geraldine
Verney, Julien
Fogli, Anne
Sapin, Vincent
Duclos, Martine
Vinet, Agnès
Obert, Philippe
Courteix, Daniel
Lac, Gérard
author_facet Dutheil, Frédéric
Walther, Guillaume
Chapier, Robert
Mnatzaganian, George
Lesourd, Bruno
Naughton, Geraldine
Verney, Julien
Fogli, Anne
Sapin, Vincent
Duclos, Martine
Vinet, Agnès
Obert, Philippe
Courteix, Daniel
Lac, Gérard
author_sort Dutheil, Frédéric
collection PubMed
description BACKGROUND: We aimed to comprehensively evaluate lipoprotein profile including lipid particle size following a lifestyle intervention in metabolic syndrome (MetS) volunteers and to assess the associations between lipoprotein subfractions and carotid-intima-media-thickness (CIMT) – a surrogate indicator of atherogenesis. METHODS: 100 participants (50–70 years) from the RESOLVE trial, underwent a one-year follow-up beginning with a three-week residential program combining high exercise volume (15-20 h/week), restrictive diet (-500 kcal/day), and education. For baseline references, 40 aged-matched healthy controls were recruited. Independent associations between subfractions of lipoproteins and CIMT were evaluated using a generalized estimating equations model accounting for variation in correlations between repeated measures. The lipoprotein subfractions profile was assessed using Lipoprint® electrophoresis allowing to separate: the very low-density lipoprotein (VLDL) fraction, then the intermediate-density lipoprotein (IDL) C, B and A, the low-density lipoprotein (LDL) with subfractions 1 and 2 as large LDL and subfractions 3 to 7 as small dense LDL (sdLDL), and the high density lipoprotein (HDL) subfractions categorized into large, intermediate, and small HDL. Apolipoproteins A1 and B were also measured. RESULTS: 78 participants completed the program. At baseline, apolipoproteins B/A1, VLDL, sdLDL and small HDL were higher in MetS than in healthy controls; IDL, LDL size, large and intermediate HDL were lower. Despite time-related regains during the follow-up, lipoprotein subfractions traditionally involved in cardiovascular risk, such as sdLDL, improved immediately after the residential program with values closest to those of healthy controls. CIMT improved throughout the lifestyle intervention. Using a generalized estimating equations model, none of the subfractions of lipoproteins nor apolipoproteins were linked to CIMT. CONCLUSIONS: Lipoprotein subfractions traditionally involved in CVR, decreased after the 3-week residential program. During a 12 month follow-up, the time-related regains remained closer to the values of healthy controls than they were at baseline. CIMT improved throughout the lifestyle intervention. However, we failed to demonstrate a link between some lipoprotein subfractions and the atherogenicity directly measured from the wall thickness of arteries (CIMT). Further investigations are required to explore the atherogenicity of lipoprotein subfractions. TRIAL REGISTRATION: NCT00917917
format Online
Article
Text
id pubmed-4115215
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-41152152014-07-31 Atherogenic subfractions of lipoproteins in the treatment of metabolic syndrome by physical activity and diet – the RESOLVE trial Dutheil, Frédéric Walther, Guillaume Chapier, Robert Mnatzaganian, George Lesourd, Bruno Naughton, Geraldine Verney, Julien Fogli, Anne Sapin, Vincent Duclos, Martine Vinet, Agnès Obert, Philippe Courteix, Daniel Lac, Gérard Lipids Health Dis Research BACKGROUND: We aimed to comprehensively evaluate lipoprotein profile including lipid particle size following a lifestyle intervention in metabolic syndrome (MetS) volunteers and to assess the associations between lipoprotein subfractions and carotid-intima-media-thickness (CIMT) – a surrogate indicator of atherogenesis. METHODS: 100 participants (50–70 years) from the RESOLVE trial, underwent a one-year follow-up beginning with a three-week residential program combining high exercise volume (15-20 h/week), restrictive diet (-500 kcal/day), and education. For baseline references, 40 aged-matched healthy controls were recruited. Independent associations between subfractions of lipoproteins and CIMT were evaluated using a generalized estimating equations model accounting for variation in correlations between repeated measures. The lipoprotein subfractions profile was assessed using Lipoprint® electrophoresis allowing to separate: the very low-density lipoprotein (VLDL) fraction, then the intermediate-density lipoprotein (IDL) C, B and A, the low-density lipoprotein (LDL) with subfractions 1 and 2 as large LDL and subfractions 3 to 7 as small dense LDL (sdLDL), and the high density lipoprotein (HDL) subfractions categorized into large, intermediate, and small HDL. Apolipoproteins A1 and B were also measured. RESULTS: 78 participants completed the program. At baseline, apolipoproteins B/A1, VLDL, sdLDL and small HDL were higher in MetS than in healthy controls; IDL, LDL size, large and intermediate HDL were lower. Despite time-related regains during the follow-up, lipoprotein subfractions traditionally involved in cardiovascular risk, such as sdLDL, improved immediately after the residential program with values closest to those of healthy controls. CIMT improved throughout the lifestyle intervention. Using a generalized estimating equations model, none of the subfractions of lipoproteins nor apolipoproteins were linked to CIMT. CONCLUSIONS: Lipoprotein subfractions traditionally involved in CVR, decreased after the 3-week residential program. During a 12 month follow-up, the time-related regains remained closer to the values of healthy controls than they were at baseline. CIMT improved throughout the lifestyle intervention. However, we failed to demonstrate a link between some lipoprotein subfractions and the atherogenicity directly measured from the wall thickness of arteries (CIMT). Further investigations are required to explore the atherogenicity of lipoprotein subfractions. TRIAL REGISTRATION: NCT00917917 BioMed Central 2014-07-11 /pmc/articles/PMC4115215/ /pubmed/25015177 http://dx.doi.org/10.1186/1476-511X-13-112 Text en Copyright © 2014 Dutheil et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Dutheil, Frédéric
Walther, Guillaume
Chapier, Robert
Mnatzaganian, George
Lesourd, Bruno
Naughton, Geraldine
Verney, Julien
Fogli, Anne
Sapin, Vincent
Duclos, Martine
Vinet, Agnès
Obert, Philippe
Courteix, Daniel
Lac, Gérard
Atherogenic subfractions of lipoproteins in the treatment of metabolic syndrome by physical activity and diet – the RESOLVE trial
title Atherogenic subfractions of lipoproteins in the treatment of metabolic syndrome by physical activity and diet – the RESOLVE trial
title_full Atherogenic subfractions of lipoproteins in the treatment of metabolic syndrome by physical activity and diet – the RESOLVE trial
title_fullStr Atherogenic subfractions of lipoproteins in the treatment of metabolic syndrome by physical activity and diet – the RESOLVE trial
title_full_unstemmed Atherogenic subfractions of lipoproteins in the treatment of metabolic syndrome by physical activity and diet – the RESOLVE trial
title_short Atherogenic subfractions of lipoproteins in the treatment of metabolic syndrome by physical activity and diet – the RESOLVE trial
title_sort atherogenic subfractions of lipoproteins in the treatment of metabolic syndrome by physical activity and diet – the resolve trial
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4115215/
https://www.ncbi.nlm.nih.gov/pubmed/25015177
http://dx.doi.org/10.1186/1476-511X-13-112
work_keys_str_mv AT dutheilfrederic atherogenicsubfractionsoflipoproteinsinthetreatmentofmetabolicsyndromebyphysicalactivityanddiettheresolvetrial
AT waltherguillaume atherogenicsubfractionsoflipoproteinsinthetreatmentofmetabolicsyndromebyphysicalactivityanddiettheresolvetrial
AT chapierrobert atherogenicsubfractionsoflipoproteinsinthetreatmentofmetabolicsyndromebyphysicalactivityanddiettheresolvetrial
AT mnatzaganiangeorge atherogenicsubfractionsoflipoproteinsinthetreatmentofmetabolicsyndromebyphysicalactivityanddiettheresolvetrial
AT lesourdbruno atherogenicsubfractionsoflipoproteinsinthetreatmentofmetabolicsyndromebyphysicalactivityanddiettheresolvetrial
AT naughtongeraldine atherogenicsubfractionsoflipoproteinsinthetreatmentofmetabolicsyndromebyphysicalactivityanddiettheresolvetrial
AT verneyjulien atherogenicsubfractionsoflipoproteinsinthetreatmentofmetabolicsyndromebyphysicalactivityanddiettheresolvetrial
AT foglianne atherogenicsubfractionsoflipoproteinsinthetreatmentofmetabolicsyndromebyphysicalactivityanddiettheresolvetrial
AT sapinvincent atherogenicsubfractionsoflipoproteinsinthetreatmentofmetabolicsyndromebyphysicalactivityanddiettheresolvetrial
AT duclosmartine atherogenicsubfractionsoflipoproteinsinthetreatmentofmetabolicsyndromebyphysicalactivityanddiettheresolvetrial
AT vinetagnes atherogenicsubfractionsoflipoproteinsinthetreatmentofmetabolicsyndromebyphysicalactivityanddiettheresolvetrial
AT obertphilippe atherogenicsubfractionsoflipoproteinsinthetreatmentofmetabolicsyndromebyphysicalactivityanddiettheresolvetrial
AT courteixdaniel atherogenicsubfractionsoflipoproteinsinthetreatmentofmetabolicsyndromebyphysicalactivityanddiettheresolvetrial
AT lacgerard atherogenicsubfractionsoflipoproteinsinthetreatmentofmetabolicsyndromebyphysicalactivityanddiettheresolvetrial